Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

While uncertainty often casts a shadow on the Street, U.S. investors welcomed the presidential and congressional election ...

Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is paving for them, according to a panel of executives who spoke at the BioFuture ...

Researchers at Harvard Medical School have found that blocking the neuron-released peptide CGRP decreases pain sensitivity and reduces lesion size in endometriosis. Endometriosis is a painful, steroid ...

Celltrion Inc. posted preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71 – at ...

The EU’s still-new regulations for medical devices and in vitro diagnostics are often seen as drivers of current or impending shortages of these products, but Oliver Eikenberg of regulatory ...

Tevogen Bio Inc. has begun preclinical efforts for TVGN-920, its first oncology product. The company is leveraging ...

Scientists from the University of Wisconsin-Madison have reported the discovery of novel carbonic anhydrase IX (CAIX) ...

I think elections are like pregnancy. … Everyone puts all of the energy into D-day – the birth. We’ve had the gender reveal, but what really, really matters is what happens now and the path ahead.” ...

Avacta Life Sciences (Avacta Group plc) presented preclinical data on AVA-6103, a second-generation Precision peptide-drug conjugate, being developed for the potential treatment of cancer. AVA-6103 ...

OSE Therapeutics SA has reported positive data for lusvertikimab in a phase II trial in ulcerative colitis, boosting the ...

Shanghai Yidi Biotechnology Co. Ltd. has patented dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or PDE4D2 inhibitors reported to be useful for the treatment of autoimmune, ...